[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts
Research output: Contribution to journal › Journal article › Research › peer-review
APO866 is a new anti-tumor compound inhibiting nicotinamide phosphoribosyltransferase (NAMPT). APO866 has an anti-tumor effect in several pre-clinical tumor models and is currently in several clinical phase II studies. 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) is a tracer used to assess cell proliferation in vivo. The aim of this study was non-invasively to study effect of APO866 treatment on [18F]FLT and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake.
| Original language | English |
|---|---|
| Article number | e53410 |
| Journal | P L o S One |
| Volume | 8 |
| Issue number | 1 |
| Pages (from-to) | 1-8 |
| Number of pages | 9 |
| ISSN | 1932-6203 |
| DOIs | |
| Publication status | Published - 2013 |
ID: 45864162